Eli Lilly (LLY) and Novo Nordisk (NVO) have been two of the market's biggest success stories this year thanks to booming demand for their new diabetes/weight loss drugs, Mounjaro, Ozempic, and Wegovy, states Chris Preston of Cabot Wealth Network.
How long will their rally last? And is the corresponding selloff in Consumer Staples totally overdone? Chris Preston and Brad Simmerman discussed on the latest episode of Cabot Street Check.
Learn more about Cabot Wealth Network here.
Subscribe to MoneyShow’s daily investment newsletter Top Pros' Top Picks and get actionable advice from our top experts, including the hottest stocks to buy and sell, ETFs and funds for short- and long-term capital appreciation, and a wide variety of dividend-paying stocks set to deliver a steady stream of safe, reliable income.
Get an edge on the markets with our weekly trading newsletter, Trading Insights, and receive timely trade ideas covering stocks, options, futures, and more to keep you on the right side of the action. From trading basics to advanced strategies and high-probability set-ups, the insights you need from our all-star lineup of trading pros is delivered straight to your inbox.
The stock market offers virtually any combination of long-term opportunities for growth and income, as well as short-term investments for trading gains. MoneyShow’s weekly Virtual Learning Letter showcases a variety of on-demand webcasts and video market commentary by top financial experts covering the hottest financial topics each week.
